With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling
The system is powered by BrainSense technology, which has received approval from USFDA
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
Subscribe To Our Newsletter & Stay Updated
